Working... Menu

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01273896
Recruitment Status : Completed
First Posted : January 11, 2011
Results First Posted : November 20, 2015
Last Update Posted : November 20, 2015
Synta Pharmaceuticals Corp.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

The purpose of this study is to find out what effects, good and/or bad, STA-9090 has on the patient and their breast cancer.

STA-9090 is an experimental drug that works by breaking down cancer proteins. When the cancer proteins are destroyed, the cancer cells die. STA-9090 is an experimental drug that is not yet approved for the treatment of cancer by the United States (FDA) Food and Drug Administration . STA-9090 has been tested in cancer patients in other trials and a safe dose for this drug has been found. We are now interested to see how active this drug is against breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: STA-9090 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Study Start Date : January 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: STA-9090
This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
Drug: STA-9090
All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Radiological imaging studies to evaluate tumor status will be repeated during the rest week (Days 22 to 28) of every third cycle ]
    To determine the overall response rate using RECIST v 1.1 criteria, defined as PR +CR.using RECIST v 1.1 criteria, defined as Partial response + complete response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and Female patients must be at least 18 years of age
  • Pathologically confirmed diagnosis of breast cancer
  • Metastatic or advanced stage breast cancer
  • Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy)
  • Patients with HER2+ disease must have received prior treatment with Trastuzumab
  • Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy
  • Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) ≥ 3 weeks
  • Measurable disease by RECIST 1.1
  • Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Life expectancy of at least 3 months
  • Adequate hematologic function as defined by:
  • Absolute neutrophil count ≥1,500 cells/μL
  • Platelets ≥100,000/μL
  • Hemoglobin ≥ 9.0g/dL
  • Adequate hepatic function as defined by:
  • Serum bilirubin ≤ 1.5 X upper limit of normal (ULN);
  • Adequate renal function as defined by a serum creatinine ≤ 1.5 x ULN
  • AST, ALT, and alkaline phosphatase ≤ 3 × ULN except for:
  • Patients with hepatic metastases: ALT and AST ≤ 5 × ULN
  • Patients with hepatic and/or bone metastases: alkaline phosphatase ≤ 5 × ULN
  • Patients with Gilbert's disease: serum bilirubin < 5 mg/dL
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Female subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment
  • Female subjects of childbearing age must have a negative serum pregnancy test at study entry.

Exclusion Criteria:

  • Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease
  • Major surgery within 4 weeks prior to first dose of STA-9090
  • Poor peripheral venous access for study drug administration. Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material.
  • History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol [PEG] 300 and Polysorbate 80)
  • Baseline QTc > 470 msec
  • Ventricular ejection fraction (EF) <50% at baseline
  • Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)
  • Women who are pregnant or lactating
  • Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results in the judgment of the investigator
  • Seizure disorder or requirement for seizure medication
  • Prior treatment with an HSP90 inhibitor
  • persistent adverse events of prior therapies that are > 1 grade 1 in severity
  • history of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery
  • history of or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block
  • New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers or diuretics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01273896

Layout table for location information
United States, New Jersey
Memorial Sloan-Kettering at Basking Ridge
Basking Ridge, New Jersey, United States, 07920
United States, New York
Memorial Sloan-Kettering Cancer Center at Commack
Commack, New York, United States, 11725
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Rockville Centre, New York, United States, 11570
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow, New York, United States, 10591
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Synta Pharmaceuticals Corp.
Layout table for investigator information
Principal Investigator: Shanu Modi, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT01273896     History of Changes
Other Study ID Numbers: 10-145
First Posted: January 11, 2011    Key Record Dates
Results First Posted: November 20, 2015
Last Update Posted: November 20, 2015
Last Verified: October 2015

Keywords provided by Memorial Sloan Kettering Cancer Center:
advanced breast cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases